The Russian Biopharmaceuticals and Biomedicine Market

From Import Substitution to Innovation

Regular Price: USD 1,500

Special Price USD 1,350

10% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,350

PAY BY INVOICE

Be the first to review this product

This study covers the Russian biopharmaceutical and biomedicine markets. Key segments for the biopharmaceutical market include cytokines, monoclonal antibodies, vaccines, and antibiotics. The biomedicine market includes regenerative medicine, nanomedicine, biocompatible medical materials, diagnostics, post-genomic technologies, and bioinformatics. This research shows the latest developments in Russian biotechnology, defines key segments and emerging leaders, and outlines government policies and support mechanisms. The base year for the study is 2013 with a forecast period of 2014 to 2018.

Table of Contents

The Russian Biopharmaceuticals and Biomedicine MarketExecutive SummaryExecutive Summary (continued)Executive SummaryKey Companies to Watch in 2015Research Scope and ObjectiveRussian Economy SnapshotRussian Economy OverviewHealthcare Market OverviewBiopharmaceuticals Market OverviewBiopharmaceuticals Market OverviewBiopharmaceuticals Market Overview (continued)Market DriversDrivers—ExplainedMarket RestraintsRestraints—ExplainedRussian Biopharmaceuticals Market—Revenue ForecastRegulatory EnvironmentComplex Program for Development of Biotechnology in the Russian Federation Until 2020Complex Program for Development of Biotechnology in the Russian Federation Until 2020 (continued)Key Government Support Mechanisms—Overview Key Government Support Mechanisms—Biotech ClustersKey Government Support Mechanisms—Biotech Clusters (continued)Key Government Support Mechanisms—Technology PlatformsKey Government Support Mechanisms—ZHNVLP List and Import SubstitutionBiotechnology Investment—State Development InstitutionsBiotechnology Investment—Venture CapitalBiopharmaceuticals Market—Percent Revenue Breakdown by SegmentBiopharmaceuticals—Cytokines, PKI and Coagulants, Hormones, and Monoclonal Antibodies SegmentsBiopharmaceuticals Segment Overview—CytokinesBiopharmaceuticals Segment Overview—PKI and CoagulantsBiopharmaceuticals Segment Overview—Hormones Biopharmaceuticals Segment Overview—Monoclonal AntibodiesBiopharmaceuticals—Vaccines SegmentVaccines SegmentVaccines Segment (continued)Vaccines Segment (continued)Vaccines Segment (continued)Vaccines Segment (continued)Biopharmaceuticals—Antibiotics and Bacteriophages SegmentAntibiotics and BacteriophagesAntibiotics and Bacteriophages (continued)Antibiotics and Bacteriophages (continued)Biomedicine Market OverviewBiomedicine Market OverviewBiomedicine Market Overview (continued)Market DriversDrivers—ExplainedMarket RestraintsRestraints—ExplainedBiomedicine—Cell Technologies, Gene Therapy, and Regenerative Medicine SegmentCell Technologies, Gene Therapy, and Regenerative MedicineCell Technologies, Gene Therapy, and Regenerative Medicine (continued)Cell Technologies, Gene Therapy, and Regenerative Medicine (continued)Biomedicine—Nanomedicine and Targeted Drug Delivery SegmentNanomedicine and Targeted Drug DeliveryNanomedicine and Targeted Drug Delivery (continued)Biomedicine—Biocompatible and Biodegradable Medical Materials SegmentBiocompatible and Biodegradable Medical MaterialsBiocompatible and Biodegradable Medical Materials (continued)Biocompatible and Biodegradable Medical Materials—Projects of TP “Medicine of the Future”Biocompatible and Biodegradable Medical Materials—Projects of TP “Medicine of the Future” (continued)Biocompatible and Biodegradable Medical Materials—Projects of TP “Medicine of the Future” (continued)Biomedicine—Diagnostic Systems, Biochips and Biosensors SegmentDiagnostics Systems, Biochips, and BiosensorsDiagnostics Systems, Biochips, and Biosensors (continued)Diagnostics Systems, Biochips, and Biosensors (continued)Biomedicine—Systems Biology, Post-genomics Technologies, and Bioinformatics SegmentsSystems Biology, Post-genomics Technologies, BioinformaticsSystems Biology, Post-genomics Technologies, Bioinformatics (continued)Systems Biology, Post-genomics Technologies, Bioinformatics (continued)Systems Biology, Post-genomics Technologies, Bioinformatics (continued)The Last WordThree Big PredictionsLegal DisclaimerAppendixImport Substitution of Biopharmaceuticals From the ZHNVLP ListImport Substitution of Biopharmaceuticals From the ZHNVLP List (continued)Import Substitution of Biopharmaceuticals From the ZHNVLP List (continued)List of AcronymsThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.